Treatment with checkpoint inhibitors such as anti-PD-L1 or anti-CTLA-4 antibodies can block the immune checkpoint signaling pathways and boost the immune response against tumor cells in many types of cancer [76]. Here, CTLA4 is linked to neoplasm.